Patterns of alternative access

Unpacking the Slovak extraordinary drug reimbursement regime 2012-2016

Olga Löblová, Marcell Csanádi, Piotr Ozierański, Zoltán Kaló, Lawrence King, Martin McKee

Research output: Contribution to journalArticle

3 Downloads (Pure)

Abstract

Many countries employ "alternative access schemes" (e.g. compassionate use, early access programs, off-label use) that seek to provide patients with access to drugs not included on a positive drug list. These schemes offer flexibility to policy-makers but often lack transparency and clear rules. This ambiguity allows for dynamic responses to weaknesses in the main drug approval and reimbursement systems, but also opportunistic use by the health professionals, industry or patients. Yet, most descriptions of these schemes focus on the de jure rather than the de facto situation, presenting a potentially misleading picture. We describe one such scheme in practice: the Slovak "extraordinary reimbursement regime" (ERR), using semi-structured interviews with 18 experts and a new dataset of ERR drugs. The ERR expanded rapidly, doubling between 2012 and 2016. It combined features of four reimbursement schemes: (1) a backdoor market access for expensive drugs; (2) a compassionate use scheme for investigational drugs combined with a "legacy drugs" scheme for older unlicensed drugs; (3) a disease-specific scheme for cancer and orphan drugs; and (4) a scheme for off-label and "off-indication" drugs. These four features reflect broader challenges facing the Slovak reimbursement system. We conclude that detailed study of the type, size and evolution over time of alternative access schemes can serve as indicators of health policy objectives neglected by standard reimbursement systems.

Original languageEnglish
Pages (from-to)713-720
JournalHealth Policy
Volume123
Issue number8
Early online date8 Jun 2019
DOIs
Publication statusPublished - 31 Aug 2019

Keywords

  • Early access
  • Off-label
  • Oncology
  • Pharmaceutical pricing and reimbursement
  • Rare diseases
  • Slovakia

ASJC Scopus subject areas

  • Health Policy

Cite this

Patterns of alternative access : Unpacking the Slovak extraordinary drug reimbursement regime 2012-2016. / Löblová, Olga; Csanádi, Marcell; Ozierański, Piotr; Kaló, Zoltán; King, Lawrence; McKee, Martin.

In: Health Policy, Vol. 123, No. 8, 31.08.2019, p. 713-720.

Research output: Contribution to journalArticle

Löblová, Olga ; Csanádi, Marcell ; Ozierański, Piotr ; Kaló, Zoltán ; King, Lawrence ; McKee, Martin. / Patterns of alternative access : Unpacking the Slovak extraordinary drug reimbursement regime 2012-2016. In: Health Policy. 2019 ; Vol. 123, No. 8. pp. 713-720.
@article{9adbcd77ff2749ecb56eb38b519613ea,
title = "Patterns of alternative access: Unpacking the Slovak extraordinary drug reimbursement regime 2012-2016",
abstract = "Many countries employ {"}alternative access schemes{"} (e.g. compassionate use, early access programs, off-label use) that seek to provide patients with access to drugs not included on a positive drug list. These schemes offer flexibility to policy-makers but often lack transparency and clear rules. This ambiguity allows for dynamic responses to weaknesses in the main drug approval and reimbursement systems, but also opportunistic use by the health professionals, industry or patients. Yet, most descriptions of these schemes focus on the de jure rather than the de facto situation, presenting a potentially misleading picture. We describe one such scheme in practice: the Slovak {"}extraordinary reimbursement regime{"} (ERR), using semi-structured interviews with 18 experts and a new dataset of ERR drugs. The ERR expanded rapidly, doubling between 2012 and 2016. It combined features of four reimbursement schemes: (1) a backdoor market access for expensive drugs; (2) a compassionate use scheme for investigational drugs combined with a {"}legacy drugs{"} scheme for older unlicensed drugs; (3) a disease-specific scheme for cancer and orphan drugs; and (4) a scheme for off-label and {"}off-indication{"} drugs. These four features reflect broader challenges facing the Slovak reimbursement system. We conclude that detailed study of the type, size and evolution over time of alternative access schemes can serve as indicators of health policy objectives neglected by standard reimbursement systems.",
keywords = "Early access, Off-label, Oncology, Pharmaceutical pricing and reimbursement, Rare diseases, Slovakia",
author = "Olga L{\"o}blov{\'a} and Marcell Csan{\'a}di and Piotr Ozierański and Zolt{\'a}n Kal{\'o} and Lawrence King and Martin McKee",
note = "Copyright {\circledC} 2019 Elsevier B.V. All rights reserved.",
year = "2019",
month = "8",
day = "31",
doi = "10.1016/j.healthpol.2019.05.021",
language = "English",
volume = "123",
pages = "713--720",
journal = "Health Policy",
issn = "0168-8510",
publisher = "Elsevier Ireland Ltd",
number = "8",

}

TY - JOUR

T1 - Patterns of alternative access

T2 - Unpacking the Slovak extraordinary drug reimbursement regime 2012-2016

AU - Löblová, Olga

AU - Csanádi, Marcell

AU - Ozierański, Piotr

AU - Kaló, Zoltán

AU - King, Lawrence

AU - McKee, Martin

N1 - Copyright © 2019 Elsevier B.V. All rights reserved.

PY - 2019/8/31

Y1 - 2019/8/31

N2 - Many countries employ "alternative access schemes" (e.g. compassionate use, early access programs, off-label use) that seek to provide patients with access to drugs not included on a positive drug list. These schemes offer flexibility to policy-makers but often lack transparency and clear rules. This ambiguity allows for dynamic responses to weaknesses in the main drug approval and reimbursement systems, but also opportunistic use by the health professionals, industry or patients. Yet, most descriptions of these schemes focus on the de jure rather than the de facto situation, presenting a potentially misleading picture. We describe one such scheme in practice: the Slovak "extraordinary reimbursement regime" (ERR), using semi-structured interviews with 18 experts and a new dataset of ERR drugs. The ERR expanded rapidly, doubling between 2012 and 2016. It combined features of four reimbursement schemes: (1) a backdoor market access for expensive drugs; (2) a compassionate use scheme for investigational drugs combined with a "legacy drugs" scheme for older unlicensed drugs; (3) a disease-specific scheme for cancer and orphan drugs; and (4) a scheme for off-label and "off-indication" drugs. These four features reflect broader challenges facing the Slovak reimbursement system. We conclude that detailed study of the type, size and evolution over time of alternative access schemes can serve as indicators of health policy objectives neglected by standard reimbursement systems.

AB - Many countries employ "alternative access schemes" (e.g. compassionate use, early access programs, off-label use) that seek to provide patients with access to drugs not included on a positive drug list. These schemes offer flexibility to policy-makers but often lack transparency and clear rules. This ambiguity allows for dynamic responses to weaknesses in the main drug approval and reimbursement systems, but also opportunistic use by the health professionals, industry or patients. Yet, most descriptions of these schemes focus on the de jure rather than the de facto situation, presenting a potentially misleading picture. We describe one such scheme in practice: the Slovak "extraordinary reimbursement regime" (ERR), using semi-structured interviews with 18 experts and a new dataset of ERR drugs. The ERR expanded rapidly, doubling between 2012 and 2016. It combined features of four reimbursement schemes: (1) a backdoor market access for expensive drugs; (2) a compassionate use scheme for investigational drugs combined with a "legacy drugs" scheme for older unlicensed drugs; (3) a disease-specific scheme for cancer and orphan drugs; and (4) a scheme for off-label and "off-indication" drugs. These four features reflect broader challenges facing the Slovak reimbursement system. We conclude that detailed study of the type, size and evolution over time of alternative access schemes can serve as indicators of health policy objectives neglected by standard reimbursement systems.

KW - Early access

KW - Off-label

KW - Oncology

KW - Pharmaceutical pricing and reimbursement

KW - Rare diseases

KW - Slovakia

UR - http://www.scopus.com/inward/record.url?scp=85068227007&partnerID=8YFLogxK

U2 - 10.1016/j.healthpol.2019.05.021

DO - 10.1016/j.healthpol.2019.05.021

M3 - Article

VL - 123

SP - 713

EP - 720

JO - Health Policy

JF - Health Policy

SN - 0168-8510

IS - 8

ER -